CO6231056A2 - Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas - Google Patents

Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas

Info

Publication number
CO6231056A2
CO6231056A2 CO09111661A CO09111661A CO6231056A2 CO 6231056 A2 CO6231056 A2 CO 6231056A2 CO 09111661 A CO09111661 A CO 09111661A CO 09111661 A CO09111661 A CO 09111661A CO 6231056 A2 CO6231056 A2 CO 6231056A2
Authority
CO
Colombia
Prior art keywords
hsa
patient
expression
treatment
post
Prior art date
Application number
CO09111661A
Other languages
English (en)
Spanish (es)
Inventor
Jian-Wei Chen
Sung-Liang Yu
Hsuan-Yu Chen
Gee-Chen Chang
Chih-Yi Chen
Pan-Chyr Yang
Original Assignee
Univ Nat Taiwan
Dcb Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Taiwan, Dcb Usa Llc filed Critical Univ Nat Taiwan
Publication of CO6231056A2 publication Critical patent/CO6231056A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO09111661A 2007-04-10 2009-10-08 Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas CO6231056A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91099307P 2007-04-10 2007-04-10

Publications (1)

Publication Number Publication Date
CO6231056A2 true CO6231056A2 (es) 2010-12-20

Family

ID=39831416

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09111661A CO6231056A2 (es) 2007-04-10 2009-10-08 Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas

Country Status (13)

Country Link
US (1) US7745134B2 (cg-RX-API-DMAC10.html)
EP (1) EP2134874A4 (cg-RX-API-DMAC10.html)
JP (1) JP2010523156A (cg-RX-API-DMAC10.html)
KR (1) KR20100027102A (cg-RX-API-DMAC10.html)
CN (1) CN101688240A (cg-RX-API-DMAC10.html)
AU (1) AU2008237036A1 (cg-RX-API-DMAC10.html)
CA (1) CA2695868A1 (cg-RX-API-DMAC10.html)
CO (1) CO6231056A2 (cg-RX-API-DMAC10.html)
IL (1) IL201298A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009010899A (cg-RX-API-DMAC10.html)
RU (1) RU2009141359A (cg-RX-API-DMAC10.html)
TW (1) TWI367949B (cg-RX-API-DMAC10.html)
WO (1) WO2008124777A1 (cg-RX-API-DMAC10.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016548A2 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
JP2010516291A (ja) 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性白血病（ａｍｌ）の診断、予後及び治療のためのマイクロｒｎａに基づく方法及び組成物
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
EP2173911B1 (en) 2007-07-31 2014-06-18 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
EP2196543A1 (en) * 2008-12-15 2010-06-16 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expression profiling of hepatocellular cancer
WO2010094155A1 (en) * 2009-02-23 2010-08-26 Capitalbio Corporation Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival
CN101638656B (zh) * 2009-08-28 2011-05-11 南京医科大学 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
MX342967B (es) * 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
US20110223607A1 (en) * 2010-03-12 2011-09-15 Quest Diagnostics Investments Incorporated Circulating microrna as a marker for hepatocellular carcinoma
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
JP2014509852A (ja) 2011-03-07 2014-04-24 ジ・オハイオ・ステート・ユニバーシティ マイクロＲＮＡ−１５５（ｍｉＲ−１５５）により誘導される変異誘発活性は炎症および癌を結び付ける
US8404437B2 (en) 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer
WO2012151212A1 (en) * 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
JPWO2013038737A1 (ja) 2011-09-16 2015-03-23 Ｌｓｉｐファンド運営合同会社 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
EP2790735A4 (en) 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
US9850541B2 (en) * 2011-12-19 2017-12-26 Valley Health System Methods and kits for detecting subjects at risk of having cancer
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
US10738363B2 (en) 2016-08-31 2020-08-11 National Central University Analyzer and analytical method for predicting prognosis of cancer radiotherapy
DE102018110526A1 (de) 2018-05-02 2019-11-07 Faurecia Autositze Gmbh Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz
CN108648826B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108320806B (zh) * 2018-05-09 2022-04-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN108630317B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
CN108733980B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法
CN108363907B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
CN108647493B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种肾透明细胞癌个性化预后评估方法
CN108470111B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108611416B (zh) * 2018-05-09 2020-12-29 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
US11410745B2 (en) * 2018-06-18 2022-08-09 International Business Machines Corporation Determining potential cancer therapeutic targets by joint modeling of survival events
TWI758670B (zh) * 2018-12-24 2022-03-21 奎克生技光電股份有限公司 健康風險評估方法
CN111172285A (zh) * 2020-02-26 2020-05-19 江南大学附属医院 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用
TWI878107B (zh) * 2024-04-30 2025-03-21 朱旆億 乳癌預後存活率預測模型建立方法及系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029287A2 (en) * 2002-09-27 2004-04-08 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
ATE546528T1 (de) * 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
EP1713938A2 (en) * 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US20050272067A1 (en) * 2004-03-10 2005-12-08 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20060078913A1 (en) * 2004-07-16 2006-04-13 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling

Also Published As

Publication number Publication date
EP2134874A1 (en) 2009-12-23
TWI367949B (en) 2012-07-11
JP2010523156A (ja) 2010-07-15
WO2008124777A1 (en) 2008-10-16
CN101688240A (zh) 2010-03-31
AU2008237036A2 (en) 2010-09-09
AU2008237036A1 (en) 2008-10-16
KR20100027102A (ko) 2010-03-10
IL201298A0 (en) 2010-05-31
CA2695868A1 (en) 2008-10-16
TW200912002A (en) 2009-03-16
RU2009141359A (ru) 2011-05-20
US7745134B2 (en) 2010-06-29
MX2009010899A (es) 2010-02-17
US20080254473A1 (en) 2008-10-16
EP2134874A4 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
RU2009141359A (ru) Посттерапевтический прогноз выживания больных раком с использованием микрорнк
Chen et al. Drug resistance‐related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies
Li et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance
Grosso et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines
US9745630B2 (en) MiRNA fingerprint in the diagnosis of prostate cancer
MX2010004916A (es) Proceso para predecir el pronostico de cancer en celulas escamosas de pulmon.
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
Vandenboom Ii et al. MicroRNA and cancer: tiny molecules with major implications
ES2721639T3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
PH12013501940A1 (en) Fused tricyclic dual inhibitors of cdk 4/6 and flt3
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
EA201171335A1 (ru) Вектор гена
SG10201803845SA (en) Pyrazole derivatives as modulators of calcium release -activated calcium channel
RU2014117666A (ru) Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами атr
ES2527592T3 (es) Métodos basados en microARN para el diagnóstico del cáncer de colon
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
Dai et al. CircRNA UBAP2 facilitates the progression of colorectal cancer by regulating miR-199a/VEGFA pathway.
Rodriguez-Rodero et al. Epigenetic modulators of thyroid cancer
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
CR20110479A (es) Combinaciones farmaceuticas que comprenden rdea 119/bay 869766 para el tratamiento de canceres especificos
Dundar et al. Overexpression of miR-21 Is Associated With Recurrence in Patients With Hepatitis B Virus–Mediated Hepatocellular Carcinoma Undergoing Liver Transplantation
Guo et al. miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms
TW200738253A (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
Chai et al. Clinical implications of microRNAs in liver cancer stem cells

Legal Events

Date Code Title Description
FA Application withdrawn